

SCHOOL OF PUBLIC HEALTH

Department of Global Health and Population

Poverty, equity & TB control

Stéphane Verguet

Department of Global Health and Population, Harvard T.H. Chan School of Public Health

Email: verguet@hsph.harvard.edu

47th Union World Conference on Lung Health, October 29, 2016, Liverpool, United Kingdom

Acknowledgements

BILL&MELINDA GATES foundation

Carlos Riumallo-Herl, Gabriela Gomez,
Nicolas Menzies, Rein Houben, Tom Sumner,
Marek Lalli, Richard White, Joshua Salomon,
Ted Cohen, Nicola Foster, Susmita Chatterjee,
Sedona Sweeney, Inés Garcia Baena,
Knut Lönnroth, Diana Weil, Anna Vassall



Outline

Background

The post-2015 agenda and the discourse on poverty

Economic evaluation for health policy assessment

Quantifying the efficient purchase of poverty reduction & equity

Application to TB control in South Africa & India

Poverty impact of: (i) improved drug sensitive TB care; (ii) improved MDR-TB care; (iii) intensified case finding

Conclusions

Priority setting & anchoring TB control within the poverty alleviation agenda



Background

The post-2015 agenda and the discourse on poverty



End of poverty by 2030

Sustainable Development Goal 1

"End poverty in all its forms everywhere"




World Bank objectives

- (1) To eradicate extreme poverty (< \$1.90 per day) by 2030
- (2) To boost shared prosperity by raising the incomes of the bottom 40% of populations



Trends in poverty




Cruz et al. World Bank 2015



Aspirational poverty by 2030

Simulations of poverty rate in 2030 (percent), by region and world



Sustainable Development Goal 3

"Achieve universal health coverage, including financial risk protection for all"



How to achieve the poverty objective by 2030?

Usual requirements are put forward:

- **Sustaining growth:** leadership and governance, macroeconomic stability, market orientation
- Investing in human development: education, health
- Insuring against risks: social policies and programs, insurance



THEY LACK OF SPECIFIC PROPOSITIONS AND QUANTIFICATION OF IMPACT AND COST




Economic evaluation for health policy assessment

Quantifying the "efficient purchase" of poverty reduction & equity



Policy objective: "efficient" purchase of poverty reduction, financial risk protection

\$ per Financial Risk Protection provided (e.g. \$ per poverty case



Health Policy Assessment, with dimensions of equity & medical impoverishment

Extended Cost-Effectiveness Analysis (ECEA)

- (1) Distributional consequences across distinct strata of populations (e.g. socio-economic status, geographical setting, gender)
- (2) Financial risk protection: quantify household medical impoverishment averted by policy



Application to TB control

Poverty impact of: (i) improved drug sensitive TB care; (ii) improved MDR-TB care; (iii) intensified case finding



Objective

To estimate poverty impact (2016-35) in India & South Africa of:

Improved drug sensitive TB care – India & South Africa

Improvement in quality increasing treatment success rate, with financial incentives and improved nutrition

Improved MDR-TB – India & South Africa

Improvement in quality increasing treatment success rate, with financial incentives and improved nutrition

Intensified case finding – South Africa

All individuals seeking health services are screened for TB



Model (TB-MAC)

People on Drug
Sensitive TB treatment

People on MDR-TB treatment

TB deaths

Each individual is in one household assigned given annual income and patient costs

Estimate of household catastrophic health cost (patient costs > 20% of income)

Note: Assume individuals in poorer quintiles more likely to have TB than individuals in richer quintiles & individuals in richer quintiles more likely to seek TB care than individuals in poorer quintiles



SCHOOL OF PUBLIC HEALTH

Epidemiologic inputs (over 2016-35)

Intervention	India	South Africa
Treated drug sensitive TB cases	50,000,000	6,000,000
Treated MDR-TB cases	1,000,000	200,000
TB-related deaths	7,000,000	1,000,000
Relative risk of TB disease, from poorest to richest	1; 0.7; 0.5; 0.3; 0.2	1; 0.7; 0.5; 0.3; 0.2
Relative ratio of health services utilization, from poorest to richest	0.2; 0.4; 0.6; 0.8; 1	0.7; 0.8; 0.8; 0.9; 1



Patient costs

Intervention	India	South Africa
Drug sensitive (DS) TB treatment (monthly), base case	\$61	\$38
MDR TB treatment (monthly), base case	\$61	\$123
Improved DS TB care (monthly)	\$48	\$38
Improved MDR TB care (monthly)	\$48	\$123
Funeral costs	\$300	\$1,900



Annual household income

INDIA

Quintile I	Quintile II	Quintile III	Quintile IV	Quintile V
< \$700	> \$700 < \$1,200	> \$1,200 < \$1,700	> \$1,700 < \$2,300	> \$2,500


SOUTH AFRICA

Quintile I	Quintile II	Quintile III	Quintile IV	Quintile V
< \$2,800	> \$2,800 < \$4,500	> \$4,500 < \$6,600	> \$6,600 < \$9,600	> \$9,600

Note: Drawn from Gamma distribution based on GDP per capita and Gini index




Financial risk protection afforded, 2016-2035, India





Financial risk protection afforded, 2016-2035, South Africa






Conclusions

Priority setting & anchoring TB control within the poverty alleviation agenda



Financial risk protection afforded & health gains, per \$100,000 spent



Per \$ spent

Priority
setting
within
the health
sector

Poverty alleviation benefits

Low health benefits
High poverty
alleviation benefits

High health benefits
High poverty
alleviation benefits

Low health benefits
Low poverty
alleviation benefits

High health benefits

Low poverty


alleviation benefits

Health benefits



Priority setting **beyond** the health sector

Estimate efficient purchase of poverty alleviation benefits by health policies i.e. poverty cases averted per policy 1\$M invested



Intersectoral comparison by Ministry of Finance & Development



Email:

verguet@hsph.harvard.edu

Web:

www.hsph.harvard.edu/stephane-verguet/

